Avai Bio Inc (AVAI)

[resx18]

Avant Technologies (OTCQB: AVAI) and Ainnova Tech Bolster FDA Clinical Trial Strategy and Global Reach for Vision AI Platform

FDA Clinical Trial Progress Accelerates with Enhanced Recruitment: On August 12, 2025, Avant Technologies and Ainnova Tech announced a refined patient recruitment strategy for their Vision AI platform's U.S. clinical trial, targeting 1,000 multiethnic diabetic patients across 8-10 sites in community clinics.

✅ Avant Technologies (OTCQB: $AVAI): A Rising Star in AI-Driven Healthcare Innovation

Clinical Protocol Advanced Post-FDA Feedback: July 29, 2025, marked a key milestone as Ainnova revised its clinical trial protocol based on FDA input from a mid-July meeting, with resubmission imminent.